PH12012501740A1 - Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate - Google Patents

Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

Info

Publication number
PH12012501740A1
PH12012501740A1 PH1/2012/501740A PH12012501740A PH12012501740A1 PH 12012501740 A1 PH12012501740 A1 PH 12012501740A1 PH 12012501740 A PH12012501740 A PH 12012501740A PH 12012501740 A1 PH12012501740 A1 PH 12012501740A1
Authority
PH
Philippines
Prior art keywords
methotrexate
rheumatoid arthritis
combination
amount
laquinimod
Prior art date
Application number
PH1/2012/501740A
Other languages
English (en)
Inventor
Joel Kaye
Nora Tarcic
Eran Blaugrund
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44531858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12012501740(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PH12012501740A1 publication Critical patent/PH12012501740A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2012/501740A 2010-03-03 2011-03-02 Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate PH12012501740A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33937510P 2010-03-03 2010-03-03
PCT/US2011/026885 WO2011109531A1 (en) 2010-03-03 2011-03-02 Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

Publications (1)

Publication Number Publication Date
PH12012501740A1 true PH12012501740A1 (en) 2012-11-12

Family

ID=44531858

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2012/501740A PH12012501740A1 (en) 2010-03-03 2011-03-02 Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

Country Status (22)

Country Link
US (1) US8501766B2 (enExample)
EP (1) EP2542079B1 (enExample)
JP (1) JP5819328B2 (enExample)
KR (1) KR20130014523A (enExample)
CN (2) CN102781240A (enExample)
AU (1) AU2011223697B2 (enExample)
BR (1) BR112012022187A2 (enExample)
CA (1) CA2791709A1 (enExample)
CL (1) CL2012002424A1 (enExample)
CO (1) CO6630085A2 (enExample)
DK (1) DK2542079T3 (enExample)
EA (1) EA201290860A1 (enExample)
ES (1) ES2476368T3 (enExample)
MX (1) MX2012010066A (enExample)
NZ (1) NZ602478A (enExample)
PE (1) PE20130690A1 (enExample)
PH (1) PH12012501740A1 (enExample)
PT (1) PT2542079E (enExample)
SG (1) SG183513A1 (enExample)
SI (1) SI2542079T1 (enExample)
WO (1) WO2011109531A1 (enExample)
ZA (1) ZA201207128B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101440982B1 (ko) * 2005-10-19 2014-09-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 제조방법
US7989473B2 (en) 2006-06-12 2011-08-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US8178127B2 (en) 2007-12-20 2012-05-15 Teva Pharmaceuticals Industries, Ltd. Stable laquinimod preparations
JP2012502038A (ja) * 2008-09-03 2012-01-26 テバ ファーマシューティカル インダストリーズ リミティド 免疫機能の２−オキソ−１，２−ジヒドロ−キノリンモジュレーター
DK2442651T3 (en) * 2009-06-19 2015-09-21 Teva Pharma Treatment of multiple sclerosis with laquinimod
MX2012001333A (es) * 2009-07-30 2012-06-01 Teva Pharma Tratamiento de la enfermedad de crohn con la laquinimod.
PT2467372T (pt) 2009-08-10 2016-08-23 Teva Pharma Tratamento de distúrbios relacionados com bdnf usando laquinimod
KR20160129093A (ko) * 2010-03-03 2016-11-08 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
CN104610144A (zh) 2010-07-09 2015-05-13 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
EP2766020A4 (en) 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
JP2015505564A (ja) 2012-02-03 2015-02-23 テバ ファーマシューティカル インダストリーズ リミティド 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
WO2014152009A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
US9233927B2 (en) 2013-03-14 2016-01-12 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
CN115281149A (zh) * 2021-05-12 2022-11-04 四川大学华西医院 一种临床前类风湿关节炎(Pre-RA)小鼠模型

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US6696407B1 (en) * 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
CN100390148C (zh) * 1999-10-25 2008-05-28 活跃生物技术有限公司 用于治疗恶性肿瘤的药物
AU2001278981A1 (en) * 2000-07-21 2002-02-05 Tom F Lue Prevention and treatment of sexual arousal disorders
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US6875869B2 (en) * 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
UY28391A1 (es) * 2003-06-25 2004-12-31 Elan Pharm Inc Metodos y composiciones para tratar artritis reumatoide
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
CA2561164A1 (en) * 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
CA2579038A1 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
AU2006344395B2 (en) * 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR101440982B1 (ko) * 2005-10-19 2014-09-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 나트륨의 결정 및 이의 제조방법
EP1951674B1 (en) * 2005-10-26 2011-11-23 Merck Serono SA Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
US20080108641A1 (en) * 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
LT2676967T (lt) * 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
CA2641160A1 (en) * 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
BRPI0708392A2 (pt) * 2006-03-03 2011-05-24 Elan Pharm Inc métodos de tratamento de um paciente com uma doença inflamatória ou autoimune com natalizumab e de uso de natalizumab para tratar um paciente com uma doença inflamatória ou autoimune
US9399061B2 (en) * 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2007139887A2 (en) 2006-05-22 2007-12-06 Cargill, Incorporated Methods for treating bone or joint inflammation
US7989473B2 (en) * 2006-06-12 2011-08-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
WO2007146331A1 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
ATE510538T1 (de) * 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
CN101743018A (zh) 2006-12-19 2010-06-16 梅里麦克药品公司 甲胎蛋白和免疫调谐剂的共同施用以治疗多发性硬化
US20100136125A1 (en) 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
WO2009009529A1 (en) * 2007-07-11 2009-01-15 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
US8178127B2 (en) * 2007-12-20 2012-05-15 Teva Pharmaceuticals Industries, Ltd. Stable laquinimod preparations
JP2012502038A (ja) * 2008-09-03 2012-01-26 テバ ファーマシューティカル インダストリーズ リミティド 免疫機能の２−オキソ−１，２−ジヒドロ−キノリンモジュレーター
CA2743717A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
DK2442651T3 (en) * 2009-06-19 2015-09-21 Teva Pharma Treatment of multiple sclerosis with laquinimod
MX2012001333A (es) * 2009-07-30 2012-06-01 Teva Pharma Tratamiento de la enfermedad de crohn con la laquinimod.
PT2467372T (pt) * 2009-08-10 2016-08-23 Teva Pharma Tratamento de distúrbios relacionados com bdnf usando laquinimod
KR20160129093A (ko) * 2010-03-03 2016-11-08 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
AU2011223702B2 (en) * 2010-03-03 2016-07-14 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
EP2590653A4 (en) * 2010-07-09 2014-01-01 Teva Pharma 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF
CN104610144A (zh) * 2010-07-09 2015-05-13 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
SG10201509831XA (en) * 2010-12-07 2015-12-30 Teva Pharma Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
JP2014521659A (ja) 2011-07-28 2014-08-28 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
IN2014MN00333A (enExample) 2011-07-28 2015-09-25 Teva Pharma

Also Published As

Publication number Publication date
EP2542079A4 (en) 2013-07-24
JP2013521304A (ja) 2013-06-10
US8501766B2 (en) 2013-08-06
ES2476368T3 (es) 2014-07-14
NZ602478A (en) 2014-09-26
CN102781240A (zh) 2012-11-14
ZA201207128B (en) 2014-04-30
MX2012010066A (es) 2012-10-03
EP2542079B1 (en) 2014-05-21
PE20130690A1 (es) 2013-07-07
EA201290860A1 (ru) 2013-04-30
PT2542079E (pt) 2014-07-18
AU2011223697B2 (en) 2016-07-14
EP2542079A1 (en) 2013-01-09
SI2542079T1 (sl) 2014-08-29
CA2791709A1 (en) 2011-09-09
US20110218203A1 (en) 2011-09-08
CO6630085A2 (es) 2013-03-01
DK2542079T3 (da) 2014-08-25
AU2011223697A1 (en) 2012-10-11
BR112012022187A2 (pt) 2015-09-22
JP5819328B2 (ja) 2015-11-24
SG183513A1 (en) 2012-09-27
CN105796556A (zh) 2016-07-27
CL2012002424A1 (es) 2012-12-21
WO2011109531A1 (en) 2011-09-09
KR20130014523A (ko) 2013-02-07

Similar Documents

Publication Publication Date Title
PH12012501740A1 (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
PH12012501741A1 (en) Treatment of lupus arthritis using laquinimod
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX367341B (es) Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
MX363350B (es) COMPUESTOS DE SULFONA BICÍCLICA PARA LA INHIBICIÓN DE LA ACTIVIDAD RORgamma Y EL TRATAMIENTO DE ENFERMEDADES.
IN2015DN03219A (enExample)
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
GB201115992D0 (en) Inhibitors of Nox4 expression and/or Nox4 function and their use in the prevention and treatment of nerve injury and/or neuropathic pain
WO2014028397A3 (en) Laquinimod for treatment of gaba mediated disorders
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
GB201115977D0 (en) Neurodevelopmental disorders
MX370451B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi metil)-naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.
GB201312583D0 (en) Combination and composition for treating obesity
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
WO2011156900A3 (en) Compounds, compositions and methods for treatment of multiple sclerosis
WO2012012891A8 (en) Compounds, compositions and methods for treatment of arthritis